Trial Profile
Study of safety and efficacy of daclatasvir at doses other than 60mg daily in HIV/HCV co-infected subjects: data from the ICONA.HepaICONA foundation cohorts
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2021
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 16 May 2018 New trial record
- 14 Apr 2018 Results presented at The International Liver Congress 2018